Medical devices, healthcare technology and the business of care
510(k) clearance · K260132

Jason membrane

Botiss Biomaterials GmbH · Decision date Nov 8, 2026

MEDTECHLEDGER EXPLANATIONK260132

What did the FDA decide?

FDA recorded a substantially equivalent decision for Jason membrane, a traditional 510(k) submitted by Botiss Biomaterials GmbH of Zossen, Germany. The record lists the device under product code NPL, classification name Barrier, Animal Source, Intraoral, regulation number 872.3930, with Dental as the medical specialty and review panel. The application number and document record identifier are both K260132, received 01/16/2026, with the decision dated 11/08/2026. Substantially equivalent means clearance to market, not premarket approval.

The record does not describe the specific components, materials, or changes distinguishing this submission, nor does it identify a predicate device or summarize the basis for the equivalence finding. Those details would sit in the underlying 510(k) review documents rather than the database entry. No clinical performance, efficacy, or patient-selection information is stated here, and none should be inferred from the clearance alone.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Dental
Decision date
Nov 8, 2026
FDA decision documents: 510(k) Premarket Notification

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K260132
Regulatory pathway
510(k) premarket notification
Product code
NPL
Decision code
SESE
Decision date
Nov 8, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Barrier, Animal Source, Intraoral.

Product code
NPL
FDA device class
2

FDA decision timeline

  1. K260132 received

    Application receipt date recorded by FDA.

  2. K260132 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code NPL

Product / regulatory recordCompanyPathwayDecision dateSource
Maxigen Biotech, Inc.510(k) clearanceNov 4, 2026FDA
OSSIX PlusK262415
Datum Dental, Ltd.510(k) clearanceOct 29, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Botiss Biomaterials GmbH

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Zossen

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records